Category

Archives

Development of UPLC method for simultaneous assay of some COVID-19 drugs utilizing novel instrumental standard addition and factorial design

A green, rapid, and simple RP-UPLC method was developed and optimized by full factorial design for the simultaneous separation of oseltamivir phosphate, daclatasivir dihydrochloride, and remdesivir, with dexamethasone as a co-administered drug. The separation was established on a UPLC column BEH C18 1.7 µm (2.1 × 100.0 mm) connected with a UPLC pre-column BEH 1.7 µm (2.1 × 5.0 mm) at 25 °C with an injection volume of 10 µL. The detector (PDA) was set at 239 nm. The mobile phase consisted of methanol and ammonium acetate (8.1818 mM) in a ratio of 75.7: 24.3 (v/v). The flow rate was set at 0.048 mL min-1. The overall separation time was 9.5 min. The retention times of oseltamivir phosphate, dexamethasone, daclatasivir dihydrochloride, and remdesivir were 6.323 ± 0.145, 7.166 ± 0.036, 8.078 ± 0.124, and 8.572 ± 0.166 min (eight replicates), respectively. The proposed method demonstrated linearity in the ranges of 10.0-500.0 (ng mL-1) and 0.5-30.0 (µg mL-1) for oseltamivir phosphate, 50.0-5000.0 (ng mL-1) for dexamethasone, 25.0-1000.0 (ng mL-1) and 0.5-25.0 (µg mL-1) for daclatasvir dihydrochlorde, and 10.0-500.0 (ng mL-1) and 0.5-30.0 (µg mL-1) for remdesivir. The coefficients of determination (R2) were greater than 0.9999, with percentage recoveries greater than 99.5% for each drug. The limits of quantitation were 6.4, 1.8, 7.8, and 1.6 ng mL-1, and the limits of detection were 1.9, 0.5, 2.0, and 0.5 ng mL-1 for oseltamivir phosphate, dexamethasone, daclatasivir dihydrochloride, and remdesivir, respectively. The proposed method was highly precise, as indicated by the low percentage of relative standard deviation values of less than 1.2% for each drug. The average content and uniformity of dosage units in the studied drugs' dosage forms were determined. The average contents of oseltamivir phosphate, dexamethasone, daclatasivir dihydrochloride, and remdesivir were nearly 93%, 102%, 99%, and 95%, respectively, while the uniformity of dosage unit values were nearly 92%, 102%, 101%, and 97%. Two novel methods were established in this work. The first method was used to assess the stability of standard solutions. This novel method was based on the slope of regression equations. The second was to evaluate the excipient's interference using an innovative instrumental standard addition method. The novel instrumental standard addition method was performed using the UPLC instrument program. It was more accurate, sensitive, time-saving, economical, and eco-friendly than the classic standard addition method. The results showed that the proposed method can estimate the tested drugs' concentrations without interference from their dosage form excipients. According to the Eco-score (more than 75), the Green Analytical Procedure Index (GAPI), and the AGREE criteria (total score of 0.77), the suggested method was considered eco-friendly.

 

Comments:

The passage describes a green, rapid, and simple method developed for the simultaneous separation of four drugs using RP-UPLC. The method uses a UPLC column and pre-column, with a mobile phase consisting of methanol and ammonium acetate, and a PDA detector set at 239 nm. The method demonstrated linearity in the ranges of 10.0-500.0 (ng mL-1) and 0.5-30.0 (µg mL-1) for oseltamivir phosphate, 50.0-5000.0 (ng mL-1) for dexamethasone, 25.0-1000.0 (ng mL-1) and 0.5-25.0 (µg mL-1) for daclatasvir dihydrochlorde, and 10.0-500.0 (ng mL-1) and 0.5-30.0 (µg mL-1) for remdesivir. The method was highly precise, with low percentage of relative standard deviation values of less than 1.2% for each drug, and had percentage recoveries greater than 99.5% for each drug. The method was also eco-friendly, with an Eco-score of more than 75, a Green Analytical Procedure Index (GAPI), and AGREE criteria with a total score of 0.77. The passage also describes two novel methods that were established in this work, one to assess the stability of standard solutions and the other to evaluate the excipient's interference using an innovative instrumental standard addition method. The proposed method can estimate the tested drugs' concentrations without interference from their dosage form excipients. Finally, the passage reports the average content and uniformity of dosage units in the studied drugs' dosage forms.

Related Products

Cat.No. Product Name Information
S5062 Daclatasvir Dihydrochloride Daclatasvir is an orally available antiviral agent that inhibits the NS5A region of the hepatitis C virus (HCV) used for the treatment of chronic HCV genotype 1 and 3 infection.

Related Targets

HCV Protease